Stock Watch: StockPreacher.com issues Market Alert for Sunesis Pharmaceuticals Inc.

DALLAS, Dec. 9, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc. SNSS. The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/SNSS

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Sunesis Pharmaceuticals Inc. (SNSS) is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. As of December 31, 2008, the Company was advancing voreloxin through phase II development. Voreloxin is an anticancer quinolone derivative (AQD). As of December 31, 2008, SNSS was conducting three clinical trials of voreloxin: a phase II clinical trial (known as the REVEAL-1 trial) in previously untreated elderly patients with acute myeloid leukemia (AML), a phase Ib/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and a phase II single agent clinical trial in advanced platinum-resistant ovarian cancer patients. The Company has worldwide development and commercialization rights to voreloxin.

Message Board Search for SNSS: http://www.boardcentral.com/boards/SNSS In the report, the analyst notes:

"Revenues for the three and nine months ended September 30, 2009, were $12,500 and $3.7 million, as compared to $0.5 million and $5.4 million for the same periods in 2008. The decrease of $0.5 million between the three month periods was due to SARcode license fee revenue recognized in the 2008 period. The decrease of $1.7 million between the nine-month periods was primarily due to the completion of research funding and technology access fee amortization under the Biogen Idec collaboration in June 2008, partially offset by the recognition in the 2009 period of $1.5 million for the Biogen Idec Raf kinase inhibitor . . .

"SNSS last week announced positive data from two phase II clinical trials of the Company's lead drug candidate, voreloxin. The results highlight voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy in patients with difficult to treat acute myeloid leukemia (AML). The trial results were presented at the 51st American Society Hematology (ASH) Annual Meeting in New Orleans, La."

To read the entire report visit: http://www.stockpreacher.com/n/SNSS

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.